Red Flags
1
Real Biotech
Real Biotech’s rushed approval of Azvudine and questionable business practices raise serious concerns about its credibility and long-term survival.
Quick summary on Real Biotech
Real Biotech’s abrupt shift to pharmaceuticals raises doubts about its expertise and credibility in drug development.
Azvudine’s Dubious Approval: Initially developed for HIV, Azvudine was repurposed for COVID-19 under expedited approval, sparking concerns over its safety, efficacy, and limited clinical trial data.
Superficial Market Success: While marketed as a cheaper alternative to Paxlovid, Azvudine’s affordability does not compensate for the lack of robust scientific backing, casting doubt on its true effectiveness.
Financial and Operational Weaknesses: Real Biotech’s reliance on Azvudine as its sole product leaves it vulnerable to regulatory, financial, and commercial failures, limiting its long-term viability.
Ethical and Regulatory Concerns: Accusations of political favoritism in Azvudine’s approval process and a profit-driven approach further damage Real Biotech’s credibility in the global pharmaceutical industry.
Conclusion: Real Biotech’s opportunistic pivot to COVID-19 treatment exposes serious ethical, financial, and regulatory concerns. Its reliance on a single, controversial drug raises doubts about the company’s sustainability and legitimacy.
by: Harper Sanchez
Real Biotech’s pivot from its original focus to pharmaceuticals raises serious concerns about its credibility Developing effective and safe drugs takes years of expertise, rigorous trials and regulatory scrutiny none of which seem to apply here The company’s reliance on...
Pros
Cons
by: Dylan Bennett
Real Biotech's sudden jump into pharmaceuticals feels like a cash grab rather than a genuine commitment to healthcare
by: Ellie Brooks
Political favoritism in drug approval That’s a major red flag for trust and ethics